iBio, Inc. announced on November 16, 2026, that it presented extended preclinical data from a non-human primate study of its long-acting Activin E-targeting antibody, IBIO-610, at ObesityWeek 2026. The study included five obese non-human primates treated with IBIO-610 and six treated with a vehicle control. The treatment regimen involved initial administration every eight weeks, followed by more frequent dosing and a subsequent dose-free period.
The data, extending observations through 28 weeks, indicates that the IBIO-610 group showed a 2.3% reduction in body weight relative to the vehicle group by week 28. Changes in body weight were first observed around week 18. At week 24, the study found that total body fat was 9.6% lower, abdominal subcutaneous fat was 16.6% lower, and visceral fat was 10.96% lower in the IBIO-610 group compared to the vehicle group, while lean mass was generally maintained. Additionally, near-complete suppression of active Activin E was observed through week 28.
In addition to the IBIO-610 data, iBio disclosed preclinical findings from its amylin program. The program combines a receptor-targeting antibody with a fused peptide agonist. In vitro testing demonstrated that the antibody-peptide fusion selectively bound and activated amylin receptors 1 and 3, with minimal binding to or activation of the calcitonin receptor alone. A single-dose study in lean rats showed that those dosed with the selective amylin receptor agonist had reduced food intake over 24 hours compared to vehicle controls.
The company stated that it plans to advance selective amylin receptor agonists into further preclinical studies in diet-induced obesity models. The data is scheduled to be presented at the PEGS Europe 2026 conference and the Amylin-Based Therapeutics Summit in December 2026.